Evidence mapPaperPMID 41454175Full record

ReviewGeroScience2026

Geroscience insights into difficult-to-treat rheumatoid arthritis: the role of unhealthy aging, comorbidity, and therapeutic complexity.

Andrea Lehoczki, Zoltan Ungvari, Ágnes Szappanos, Mónika Fekete, Lilla Gunkl-Tóth, György Nagy

Abstract readReview
In one paragraph

Review in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Andrea LehoczkiInstitute of Preventive Medicine and Public Health, Semmelweis University, Budapest, Hungary.
Zoltan UngvariVascular Cognitive Impairment, Neurodegeneration, and Healthy Brain Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Ágnes SzappanosHeart and Vascular Center, Semmelweis University, Budapest, Hungary.
Mónika FeketeInstitute of Preventive Medicine and Public Health, Semmelweis University, Budapest, Hungary.
Lilla Gunkl-TóthDepartment of Rheumatology and Immunology, Semmelweis University, Budapest, Hungary.
György NagyHeart and Vascular Center, Semmelweis University, Budapest, Hungary. nagy.gyorgy2@semmelweis.hu.

Funding

European University for Well-Being 101004093/ EUniWell/EAC-A02-2019 / EAC-A02-2019-1Nemzeti Kutatási, Fejlesztési és Innovaciós Alap InnovationNemzeti Kutatási, Fejlesztési és Innovaciós Alap National Cardiovascular Laboratory Program (RRF-2.3.1-21-2022-00003)Nemzeti Kutatási, Fejlesztési és Innovaciós Alap the EKÖP-2024-9 New National Excellence Program of the Ministry for CultureNemzeti Kutatási, Fejlesztési és Innovaciós Alap TKP2021-EGA-29Nemzeti Kutatási, Fejlesztési és Innovaciós Alap TKP2021-NKTA-47
6 · The paper itself

Abstract

Difficult-to-treat rheumatoid arthritis (D2T RA) is an emerging challenge in aging populations, where disease persistence and therapeutic failure often reflect not only autoimmune dysregulation but also the cumulative effects of age-related biological changes across multiple organ systems. This review reframes D2T RA through the lens of geroscience, highlighting how immunosenescence, inflammaging, and organ system vulnerability converge to create a treatment-resistant disease phenotype. Age-associated alterations in adaptive and innate immunity-such as diminished T cell diversity, impaired regulatory function, expansion of age-associated B cells, and heightened inflammasome activation-closely intersect with the immunopathogenesis of RA. The potential contribution of clonal hematopoiesis of indeterminate potential (CHIP) to systemic inflammation and myeloid dysfunction is also discussed as a novel mechanistic link. In parallel, aging of the musculoskeletal system magnifies joint damage, sarcopenia, and pain sensitization. Furthermore, advancing age is also accompanied by multimorbidity, polypharmacy, and frailty, which in turn constrain therapeutic options and increase the risk of adverse events. We argue that D2T RA in the elderly should not be viewed in isolation, but as part of a broader syndemic of age-related diseases driven by shared inflammatory and metabolic pathways. This perspective calls for a shift toward integrated, individualized care strategies that balance efficacy, safety, and quality of life. Future directions include the development of age-adapted treatment guidelines, expanded inclusion of older adults in clinical trials, and the application of artificial intelligence and machine learning to predict high-risk trajectories and personalize management. A geroscience-informed approach offers the conceptual foundation to meet the growing complexity of RA care in aging populations.

Indexed as

AgingArthritis, RheumatoidGeroscienceAgedAntirheumatic AgentsComorbidityHumansImmunosenescenceAntirheumatic AgentsAge-related immune dysfunctionAgingBiological agingDifficult-to-treat rheumatoid arthritisElderly-onset rheumatoid arthritisFrailtyImmunosenescenceInflammagingMultimorbidityPersonalized therapeuticsPolypharmacyPrecision medicineTherapeutic resistanceUnhealthy aging

Identifiers

PMID41454175
PMCPMC12972182

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.